Navigation Links
Disseminated Adenovirus Infection Eradicated in a Pediatric Hematopoietic Stem Cell Transplantation Recipient Who Received Chimerix's Lead Antiviral CMX001
Date:2/24/2011

from the Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B, has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV infection including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, flu, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. New Clinical Study Shows RyMed InVision-Plus® IV Connector Dramatically Reduced Catheter-Related Bloodstream Infections by Over 92%
2. Reportlinker Adds Bone and Joint Infection Market to 2016 - Medical Imaging and PCR Methods to Facilitate Early Diagnosis and Treatment
3. Instead of Preventing Infections, Silver Coated Needleless IV Connectors May Actually Cause Them, a Nationally-Recognized Expert Tells National Conference on Cancer Nursing Research
4. Optimer Pharmaceuticals and Astellas Announce Collaboration to Commercialize Fidaxomicin for Clostridium difficile infection (CDI) in Europe and Certain Other Countries in Middle East, Africa and CIS
5. Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
6. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
7. Optimer Pharmaceuticals Receives Orphan Drug Designation for Fidaxomicin for the Treatment of Pediatric Clostridium difficile Infection
8. Crothall Healthcare Selects 3M™ Clean-Trace™ for Infection Control Verification
9. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
10. Sage Products and 3M Infection Prevention Announce Agreement
11. Telbivudine Given to Mothers With Hepatitis B Reduces Infection Rate in Infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... LA JOLLA, Calif. , May 21, 2013 /PRNewswire/ ... a biopharmaceutical company leading the discovery and development of ... Garry E. Menzel , Ph.D., Chief Operating Officer ... overview at the Deutsche Bank 38th Annual Healthcare Conference ... The conference is being held at the Westin Boston ...
(Date:5/21/2013)... (NASDAQ: LCAV ), a leading provider of laser ... that all nominees to the company,s Board of Directors were ... These Directors are: , William F. Bahl ... Counsel , John C. Hassan , ... Heizer III , Chairman of Manus Health Systems, Inc. ...
(Date:5/21/2013)... 21, 2013  Zacks.com announces the list of stocks ... Equity Research analysts discuss the latest news and events ... in the blog include Actavis, Inc.,s (NYSE: ACT ... (NYSE: TOT ), Petrobras (NYSE: PBR ) ... (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) Get ...
Breaking Medicine Technology:Regulus to Present at Deutsche Bank 38th Annual Healthcare Conference 2LCA-Vision Reports on Annual Meeting of Stockholders 2LCA-Vision Reports on Annual Meeting of Stockholders 3LCA-Vision Reports on Annual Meeting of Stockholders 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5
... 2011 OrbusNeich today announced that 12-month follow-up data from ... ccelerated L ining I nhibits N eointimal ... EuroIntervention demonstrated good clinical outcomes with ... the company,s Genous Stent. Target vessel failure (TVF), ...
... school hockey coach is taking the pro-active approach to ... coaches at Stevenson High School, invented the Shockwave ... risk of sustaining a concussion, including athletes, firefighters and ... is a three-step system, starting with baseline testing to ...
Cached Medicine Technology:Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 2Published Data From e-HEALING Registry Demonstrate Good Clinical Outcomes With Low Incidence of Repeat Revascularization and Stent Thrombosis for OrbusNeich's Genous™ Stent 3Shockwave System Developed to Aid Concussion Detection 2
(Date:5/21/2013)... Bradley, Illinois (PRWEB) May 21, 2013 ... living community], a BMA affordable assisted living community, is hosting ... Don'ts of Arthritis at 2 p.m. on Tuesday, May 28. ... in Dwight, Illinois, serves older adults of all incomes, including ... independence. , The Arthritis program is open to the public. ...
(Date:5/21/2013)... (May 22, 2013)Today the George Washington (GW) ... Services (SPHHS) announced the launch of the ... Health, a collaboration between SPHHS, the Maryland ... other community partners. This university-community partnership aims ... affect Latino communities through research, mutual capacity ...
(Date:5/21/2013)... 21, 2013 Patients of Dr. Michael Shenk ... lost teeth due to gum disease and would like permanent ... disease treatment with laser gum surgery. Gum disease ... highest success rate out of all tooth replacement options. ... relatively new procedure cleared by the Food and Drug Administration ...
(Date:5/21/2013)... on a large scale is the cornerstone of ... better outcomes, better value and better experience of ... patient-centered medical home model offers a viable solution ... of Health and Human Services, Agency for Healthcare ... more about the processes and determinants of successful ...
(Date:5/21/2013)... 2013 Parker Waichman LLP, a national ... injured by defective medical devices, is addressing new research ... on May 15, 2013. The study found that magnetic ... that occur in patients with metal-on-metal hip implants even ... ) , “We’ve known for quite ...
Breaking Medicine News(10 mins):Health News:Heritage Woods of Dwight Affordable Assisted Living to Host Informational Program on the Do's and Don'ts of Arthritis 2Health News:GW launches center to address health disparities in the Latino immigrant community 2Health News:GW launches center to address health disparities in the Latino immigrant community 3Health News:Shenk Dental Care Stimulates Bone Growth for Gum Disease Patients Seeking Dental Implants with Laser Gum Surgery in Atlanta, GA 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 2Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 3Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 4Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 5Health News:AHRQ-funded journal supplement offers lessons on primary care practice transformation 6Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3
... Colorado that involves door-to-door counseling in low-income Hispanic ... and "is raising questions about whether different strategies ... the Denver Rocky Mountain News reports. ... increase, which so far directed $61 million to ...
... time, physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in ... of an antibody to directly target the blood supply ... unharmed. ,The Phase I clinical trial tested ... membrane antigen (PSMA). ,PSMA has been an ...
... participation in a national study, patients being treated ... at North Shore University Hospital// (NSUH) and Long ... that an arsenic compound, coupled with standard chemotherapy ... all had newly-diagnosed acute promyelocytic leukemia, or APL, ...
... first time have used stem cells from the hair follicles ... is much more efficient than the other existing procedures and ... ,This study was undertaken by a team from Laboratory of ... York City and was published in the current issue of ...
... standard breast cancer therapy drug tamoxifen, to another one exemestane//, ... Publishing their findings in the online version of The Lancet, ... UK, and team, stood for changing treatments tracks to exemestane ... it reduced deaths by 17 percent. ,Their findings ...
... who develop lung cancer as 10 to 15 percent//. ... offer support to these estimates, in the form of similar ... of Oncology, Dr. Heather Wakelee of Stanford University in California ... lung cancer patients are women who have never smoked. ...
Cached Medicine News:Health News:First Treatment to Directly Target Tumor Blood Supply 2Health News:First Treatment to Directly Target Tumor Blood Supply 3Health News:Arsenic Compound Effective in Treating Rare Leukemia 2Health News:Arsenic Compound Effective in Treating Rare Leukemia 3Health News:New Drug Therapy for Breast Cancer Offers Hope 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: